Aclaris Therapeutics, Inc.
ACRS
$1.33
-$0.07-5.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.72M | 27.08M | 32.02M | 31.12M | 31.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.72M | 27.08M | 32.02M | 31.12M | 31.25M |
| Cost of Revenue | 66.58M | 119.31M | 127.04M | 143.24M | 156.01M |
| Gross Profit | -47.86M | -92.23M | -95.03M | -112.12M | -124.76M |
| SG&A Expenses | 22.20M | 24.56M | 26.00M | 29.57M | 31.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.25M | 86.14M | 111.28M | 131.04M | 145.76M |
| Operating Income | -52.53M | -59.06M | -79.26M | -99.92M | -114.51M |
| Income Before Tax | -132.07M | -37.37M | -59.05M | -77.63M | -88.85M |
| Income Tax Expenses | -- | -367.00K | -367.00K | -367.00K | -367.00K |
| Earnings from Continuing Operations | -132.07 | -37.00 | -58.68 | -77.26 | -88.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.07M | -37.00M | -58.68M | -77.26M | -88.48M |
| EBIT | -52.53M | -59.06M | -79.26M | -99.92M | -114.51M |
| EBITDA | -52.22M | -58.66M | -78.83M | -99.42M | -113.95M |
| EPS Basic | -1.51 | -0.52 | -0.83 | -1.09 | -1.27 |
| Normalized Basic EPS | -0.35 | -0.44 | -0.62 | -0.80 | -0.95 |
| EPS Diluted | -1.51 | -0.52 | -0.83 | -1.09 | -1.28 |
| Normalized Diluted EPS | -0.35 | -0.44 | -0.62 | -0.80 | -0.95 |
| Average Basic Shares Outstanding | 309.05M | 284.61M | 284.04M | 283.38M | 279.18M |
| Average Diluted Shares Outstanding | 309.05M | 284.61M | 284.04M | 283.38M | 279.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
